PRAMEF10: A Potential Drug Target and Biomarker for PRAME Family Members

Target Name: PRAMEF10

NCBI ID: G343071

PRAMEF10

Other Name(s): PRAME family member 10 | PRA10_HUMAN

PRAMEF10: A Potential Drug Target and Biomarker for PRAME Family Members

The PRAME (prolylated arylalanine methyltransferase) family is a group of proteins that are involved in the regulation of amino acid metabolism, including the metabolism of arylalanine, which is a key precursor of proteins, neurotransmitters, and other molecules that are important for cellular function and growth. The PRAME family has four known subunits, PRAME1 to PRAME4, and each of these subunits has unique functions in cell biology.

PRAMEF10, also known as PRAME family member 10, is a protein that is derived from the PRAME family and has been shown to have unique functions in various cellular processes. PRAMEF10 is involved in the regulation of arylalanine metabolism and has been shown to play a role in the development and progression of various diseases, including cancer.

One of the key functions of PRAMEF10 is its role in the regulation of arylalanine metabolism. Arylalanylalanine, which is a metabolite of arylalanine, is converted to another metabolite called 2-aryl-alanine aminotransferase (2-AAT) by PRAMEF10. 2-AAT is then converted to the amino acid Lys at a rate of 20% per cell division, which is critical for the growth and development of cells.

In addition to its role in arylalanylalanine metabolism, PRAMEF10 is also involved in the regulation of protein synthesis and has been shown to play a role in the development of various diseases, including cancer. For example, studies have shown that high levels of PRAMEF10 are associated with the development of cancer and that inhibiting PRAMEF10 activity may be a potential therapeutic approach for cancer treatment.

Another function of PRAMEF10 is its role in the regulation of cell adhesion. PRAMEF10 has been shown to be involved in the regulation of cell-cell adhesion and has been shown to play a role in the development of various diseases, including cancer. For example, studies have shown that high levels of PRAMEF10 are associated with the development of cancer and that inhibiting PRAMEF10 activity may be a potential therapeutic approach for cancer treatment.

In conclusion, PRAMEF10 is a protein that is derived from the PRAME family and has unique functions in various cellular processes. PRAMEF10's role in the regulation of arylalanylalanine metabolism, protein synthesis, and cell adhesion, as well as its involvement in the development and progression of various diseases, make it a potential drug target and biomarker for PRAME family members. Further research is needed to fully understand the functions of PRAMEF10 and its potential as a therapeutic approach for various diseases.

Protein Name: PRAME Family Member 10

The "PRAMEF10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRAMEF10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets